All In Biotech

Drug Trial Radar · NCT06049290

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

342

Planned (sponsor's estimate)

Start

Oct 20, 2023

Primary completion

Sep 20, 2029

Study completion Sep 20, 2029

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • LBL-034 for InjectionDrug

    Q2W; intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).
  2. Dose-limiting toxicities(DLT)Time frame: The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
  3. Maximum tolerated dose (MTD)Time frame: The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
  4. Occurrence of adverse event (AE) and serious adverse event (SAE)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • The Afliliated Hospital of Guizhou Medical Univeristy

    Guiyang, Guizhou, China · Recruiting

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Recruiting

  • The First Affiliated Hospital of Henan University

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shengyang, Liaoning, China · Recruiting

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China · Recruiting

  • Shanghai Fourth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)

    Xi’an, Shanxi, China · Recruiting

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.